Uveal melanoma: From diagnosis to treatment and the science in between

Chandrani Chattopadhyay, Dae Won Kim, Dan S. Gombos, Junna Oba, Yong Qin, Michelle D. Williams, Bita Esmaeli, Elizabeth A. Grimm, Jennifer A. Wargo, Scott E. Woodman, Sapna P. Patel

Research output: Contribution to journalReview article

112 Scopus citations

Abstract

Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age-adjusted risk is 5 per 1 million population. These less frequent melanomas are dissimilar to their more common cutaneous melanoma relative, with differing risk factors, primary treatment, anatomic spread, molecular changes, and responses to systemic therapy. Once uveal melanoma becomes metastatic, therapy options are limited and are often extrapolated from cutaneous melanoma therapies despite the routine exclusion of patients with uveal melanoma from clinical trials. Clinical trials directed at uveal melanoma have been completed or are in progress, and data from these well designed investigations will help guide future directions in this orphan disease.

Original languageEnglish (US)
Pages (from-to)2299-2312
Number of pages14
JournalCancer
Volume122
Issue number15
DOIs
StatePublished - Mar 15 2016

Keywords

  • Breast cancer 1-associated protein 1 (BAP1)
  • Choroidal melanoma
  • Diagnosis
  • Guanine nucleotide binding protein α11 (GNA11)
  • Guanine nucleotide-binding protein Q polypeptide (GNAQ)
  • Ocular melanoma
  • Review
  • Science
  • Treatment
  • Uveal melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Uveal melanoma: From diagnosis to treatment and the science in between'. Together they form a unique fingerprint.

Cite this